Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") today announced the initiation of a life-cycle management plan as the first phase in their portfolio expansion initiative. As part of this plan, Alliqua is making a number of product changes designed to increase adoption of SilverSeal(R) and Hydress(R) dressings. Alliqua intends that these ongoing planned modifications will address the needs of patients with a broader range of wounds as well as the specific needs of their various clinical customers. Customers should expect to see the first of these updated dressings in May 2013.
"We believe that these changes and the expansion of our dressing portfolio will increase the overall number of patients who can benefit from our technology. Feedback from our customers and a market survey we conducted suggests these changes are important considerations for physicians and patients when selecting a hydrogel dressing," said David Johnson, Alliqua's chief executive officer. "Our life-cycle management initiatives are designed to ensure our SilverSeal(R) and Hydress(R) products provide compelling solutions for our customers."
The Company expects to file a 510(k) application with the FDA for clearance of SilverSeal(R) incorporating additional modifications by mid 2013, after which a decision from the FDA may be forthcoming as early as the end of the year.
About Alliqua , Inc. Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal(R) brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises. Additionally, our subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.
Contacts for Alliqua , Inc .Steven Berger Chief Financial Officer 646-218-1450 email@example.com
SOURCE Alliqua, Inc.